Ranbaxy Laboratories

In the book, Eban brings the watchdog spirit to bear upon the generics manufacturing sector out of her concern for American citizens primarily. But she has ensured that her investigation also has points to ponder for the consumers in developing nations such as India.

ED raids premises of former Ranbaxy group promoters under PMLA

Officials said the raids were conducted following a case filed under the Prevention of Money Laundering Act (PMLA).

Withdraw nod for 28 drug applications of Ranbaxy: Sun Pharma

Drug major Sun Pharma today said one of its subsidiaries has voluntarily requested the US health regulator to withdraw approval for 28 Abbreviated New Drug Applications belonging to Ranbaxy Laboratories.

Pharma crusader Thakur takes India's drug regulators to court

Three years ago, Dinesh Thakur exposed how India's then largest drugmaker and his former employer, Ranbaxy Laboratories, failed to conduct proper safety and quality tests on drugs and lied to regulators about its procedures.

Sun Pharma gets CCI nod to sell two CNS divisions to Strides

Last year in September, Sun Pharma and Strides Shasun (then Strides Arcolab) had inked a pact related to Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India.

Sun Pharma recalls over 10 lakh boxes of allergy drug in US

As per the information available on the USFDA website, Ohm Laboratories Inc, a unit of Ranbaxy Laboratories, which the company acquired last year, is recalling 10,85,095 boxes for being "Superpotent Drug: Out Of Specification".

Lupin may test Rs 2600-2700: Prakash Diwan

Prakash Diwan of prakashdiwan.in is of the view that Lupin may test Rs 2600-2700.

Positive on Sun Pharma, Strides Arcolab: Deepak Shenoy

Deepak Shenoy of capitalmind.in has a positive stance on Sun Pharmaceutical Industries and Strides Arcolab.

Here are Deepak Shenoy's few trading ideas

Watch the interview of Deepak Shenoy of capitalmind.in with Latha Venkatesh and Ekta Batra on CNBC-TV18, in which he shared his readings and outlook on the market, specific stocks and sectors.

Fortis's Shivinder Singh steps down to join a spiritual org

Shivinder Mohan Singh (40), who is the co-founder of the healthcare chain will become the Non-Executive Vice-Chairman with effect from January 1, 2016, the company said in a statement.

Strides Arcolab jumps 4%, acquires Sun Pharma's CNS biz

Sun Pharmaceutical Industries and Strides Arcolab have entered into a definitive agreement to acquire erstwhile Ranbaxy‘s Solus and Solus Care for Rs 165 crore.

Sun Pharma, IDFC, SKS Micro make it to top 10 stocks

Stocks in news are: Sun Pharmaceutical Industries, Ranbaxy Laboratories, Strides Arcolab, IDBI Bank, Axis Bank, IDFC, SKS Microfinance, Hotel Leela Venture, Ashok Leyland, Asian Paints, Lupin, Tilaknagar Industries.

Sun to sell Ranbaxy's 2 divisions to Strides for Rs 165 cr

Sun Pharma and Strides have entered into a definitive agreement related to erstwhile Ranbaxy's 'Solus' and 'Solus Care' divisions operating in the central nervous system (CNS) segment in India, the company said in a statement.

Sun Pharma to sell facility in Ireland

The divestment comes on the heels of Sun Pharma Managing Director Dilip Shanghvi saying in August that the company would look at rationalising manufacturing footprint.

Like private banks, selective pharma, TCS, Infosys: Angel

Mayuresh Joshi of Angel Broking likes private banks and selective pharma names and also likes TCS, Infosys and HCL Technologies.

Like Sun Pharma, Strides Arcolab: Deepak Shenoy

Deepak Shenoy, Founder of Capitalmind.in likes Sun Pharma and Strides Arcolab and feels that pharma as a space is worth looking into.

Rupee fall to help pharma cos; top pick Lupin : JM Fin

Anmol Ganjoo of JM Financial says Lupin remains his top pick on perfect execution track records. He also says, sectoral tailwinds will help Sun Pharma, though Ranbaxy benefits are over-rated and medicines super-priced.

Sun Pharma up 5%; BoAML upgrades to buy, weak rupee to aid

BoAML is betting big on Indian pharma companies as weak rupee is positive for the sector. It says Cadila, Aurobindo and Lupin are the biggest beneficiaries of a weak rupee while Sun Pharma would see a moderate impact as it has global operations.

Like Sun Pharma, Granules India, Suven Life: Devang Mehta

Devang Mehta of Anand Rathi Financial Services likes Sun Pharma, Granules India and Suven Lifesciences.

Sun Pharma Q1 profit tanks 46% on Ranbaxy integration cost

Revenue met expectations, growing 10 percent to Rs 6,767.6 crore in June quarter compared to Rs 6,157 crore in March quarter.

Pharma's open offer for Zenotech stake gets tepid response

Drug major Sun Pharmaceutical's open offer to acquire 28.16 percent stake in Zenotech Laboratories elicited tepid response from the shareholders.

What took mighty Lupin down!

In an interview with CNBC-TV18‘s Sonia Shenoy & Latha Venkatesh, Praful Bohra, VP- Research, Religare said that Lupin‘s numbers are weak due to decline in the US business.

Wait 2-3 qtrs to buy Lupin, Sun Pharma: Prabhudas Lilladher

Pharma Analyst Surajit Pal is not very keen on holding pharma biggies, given the newsflows that are associated with them. Lupin first quarter earnings have been disappointing and Pal believes the pain is going to continue for two-three months. Another big-ticket stock Sun Pharma too have seen a steep fall after it issued profit warning.

Buy Sun Pharma for long term: Kunj Bansal

Kunj Bansal of Centrum Wealth Management is of the view that Sun Pharmaceutical Industries is a good long term buy.

Here are some top trading ideas from Kunj Bansal

Watch the interview of Kunj Bansal of Centrum Wealth Management with Latha Venkatesh & Sonia Shenoy on CNBC-TV18, in which he shared his readings and outlook on market and specific stocks.